In contrast, intraperitoneal administration of Levodopa was able to reduce motor symptoms for less than one week following the last dose in PINK1-KO rats, while it did not have a significant therapeutic benefit in ameliorating the loss of hindlimb muscle strength, a sign of corporeal fatigue that is characteristic of PD patients [46]. Here, PINK1 is linked to Parkinson disease.